Morrow, David
( Brigham and Womens Hospital
, Boston
, Massachusetts
, United States
)
Barnett, Christopher
( UCSF
, San Francisco
, California
, United States
)
Author Disclosures:
David Morrow:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Cleerly:Active (exists now)
; Research Funding (PI or named investigator):Softcell:Active (exists now)
; Consultant:Roche:Active (exists now)
; Research Funding (PI or named investigator):Roche:Active (exists now)
; Consultant:Merck:Active (exists now)
; Consultant:Regeneron:Active (exists now)
; Research Funding (PI or named investigator):Regeneron:Active (exists now)
; Research Funding (PI or named investigator):Pfizer:Active (exists now)
; Research Funding (PI or named investigator):Novartis:Active (exists now)
; Research Funding (PI or named investigator):Daiichi Sankyo:Active (exists now)
; Research Funding (PI or named investigator):AstraZeneca:Active (exists now)
; Research Funding (PI or named investigator):Anthos Therapeutics:Active (exists now)
; Research Funding (PI or named investigator):Abiomed:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Research Funding (PI or named investigator):Abbott:Active (exists now)
| Christopher Barnett:DO have relevant financial relationships
;
Consultant:Abiomed:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Research Funding (PI or named investigator):Merck:Active (exists now)
; Speaker:zoll:Past (completed)